Statements (63)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:healthcare_organization
|
gptkbp:affects |
lymphatic system
adults of any age |
gptkbp:can_lead_to |
weight loss
fever night sweats |
gptkbp:can_metastasize_to |
initial treatment
|
gptkbp:caused_by |
swelling of lymph nodes
|
gptkbp:exhibits |
fatigue
abdominal pain skin lesions pleural effusion peripheral blood involvement |
gptkbp:has_achievements |
secondary infections
|
https://www.w3.org/2000/01/rdf-schema#label |
systemic ALCL
|
gptkbp:is_a |
type of lymphoma
|
gptkbp:is_affected_by |
treatment response
|
gptkbp:is_associated_with |
autoimmune diseases
immune system dysfunction ALK gene rearrangement B symptoms poor prognosis in elderly patients |
gptkbp:is_characterized_by |
large atypical lymphoid cells
C D4 positive T-cells |
gptkbp:is_considered |
a rare cancer
a hematological malignancy a subtype of peripheral T-cell lymphoma |
gptkbp:is_linked_to |
environmental factors
genetic predisposition viral infections |
gptkbp:is_monitored_by |
blood tests
imaging follow-ups |
gptkbp:is_often_used_in |
young adults
males |
gptkbp:is_part_of |
hematologic malignancies
lymphoma classification system lymphoma treatment protocols non-Hodgkin lymphoma category |
gptkbp:is_recognized_by |
specific biomarkers
|
gptkbp:is_related_to |
gptkb:healthcare_organization
|
gptkbp:is_studied_in |
clinical trials
|
gptkbp:is_subject_to |
ongoing research
|
gptkbp:managed_by |
oncologists
|
gptkbp:occurs_in |
gptkb:Person
|
gptkbp:posthumous_recognition |
in advanced stages
|
gptkbp:recognizes |
CT scan
PET scan |
gptkbp:scientific_classification |
C D30 positive lymphoma
|
gptkbp:social_responsibility |
imaging studies
biopsy flow cytometry immunohistochemistry variable outcomes |
gptkbp:subgenres |
primary cutaneous ALCL
systemic ALCL with ALK negative systemic ALCL with ALK positive |
gptkbp:treatment |
gptkb:vaccine
radiation therapy chemotherapy targeted therapy stem cell transplant |
gptkbp:bfsParent |
gptkb:healthcare_organization
|
gptkbp:bfsLayer |
3
|